关于这一集
Walter Robinson is a bilingual public affairs executive with 30 years of policy, legislative, and regulatory experience at every level of Canadian government — from federal director of the Canadian Taxpayers Federation, where his testimony helped shape the Romanow Commission, to Chief of Staff at Ottawa City Hall, to VP roles at Innovative Medicines Canada and senior pharma leadership at Purdue. Alongside that, he's built a parallel career in rare disease and cancer advocacy: founding board member of SecondStreet.org, former board member of the Ottawa Hospital, past chair of the Ottawa Cancer Foundation, and advisory committee member with the Lundin Cancer Fund's Glioblastoma Research Program. Based in Montreal, Walter now runs his own AI and healthcare consultancy.
In this conversation, Walter walks through why Canada builds world-class upstream research — strongest recent example, a $443-million national AI strategy that funded three institutes and over 100 research chairs — and still can't get that work across the finish line into commercialized, Canadian-owned companies.
We get into why he sees the gap as structural rather than cultural: constitutional divisions between federal and provincial jurisdiction, an academic system built on publish-or-perish rather than commercialize-or-perish, and the absence of anything like the U.S. Bay-Dole Act, which gave American universities one consistent national rulebook for moving IP out of the lab in 1980. Canada, he argues, never built that predictability, and the result is a patchwork of hybrid ownership models and career bureaucrats running tech transfer offices instead of people with venture backgrounds.
Walter also gives a postmortem on Bills C-27 and C-72, both of which died on the order paper, and explains how the Carney government is resequencing that same legislative ground through Bill S-5 — sending it to the Senate first to get around federal-provincial jurisdictional fights by framing health data as economic union, not health policy. He's cautiously optimistic about the sequencing, with one caveat: government funding bodies still run on 12-to-18-month cycles while AI capability is moving weekly, and he warns that some of today's AI health investments could become "the next round of corporate welfare headlines" in five years if there's no accountability built in.
We also dig into Canada's slipping share of global clinical trials — down from 6% to 4% in five years, roughly $2.5 billion and 20,000 jobs — and why the country is strong at Phase 1 and 2 trials but stalls at Phase 3 and 4, exactly the stages where AI-driven recruitment, retention, and pharmacovigilance could help close the gap. Walter closes with a personal note: as a patient across three generations of clinical research himself, he makes the case that treating life sciences as a matter of national sovereignty isn't abstract policy — it's how Canada gets on the winning team.
This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.
If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.
🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.
🔗 Questions, feedback, or want to connect? https://augmentios.com/contact
📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter
#BreakingInnovationParalysis #CanadianInnovation #HealthSovereignty #LifeSciences #ClinicalTrials #PublicPolicy #TechTransfer
